Marc Duey bought $490 of APRE
director at Aprea Therapeutics, Inc.. 190 shares at an average of $2.58, traded Oct 14, 2024, filed Oct 16, 2024.
Score components
- +15RoleDirector
- 0Trade size$490 at market
- -5Relative to holdingsUnder 1% of holdings (0.1%)
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-108963, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 14, 2024 | POpen-market purchase Common Stock | +190 | $2.58 | $490 | 210,113 | Oct 16, 2024 |
Related signals
Other insiders at Aprea Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | APREsell Aprea Therapeutics, Inc. | Marc Duey director | $30k 6,462 shares | -3% | |
| 40Moderate | Aprea Therapeutics, Inc. | Oren Gilad President/CEO | $1,958 500 shares | +0% | |
| 49Moderate | Aprea Therapeutics, Inc. | Marc Duey director | $132k 30,000 shares | +14% | |
| 37Weak | Aprea Therapeutics, Inc. | John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | $123 50 shares | +0% | |
| 40Moderate | Aprea Therapeutics, Inc. | Oren Gilad President/CEO | $725 250 shares | +0% | |
| 37Weak | Aprea Therapeutics, Inc. | John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | $1,175 450 shares | +2% | |
| 35Weak | Aprea Therapeutics, Inc. | Oren Gilad President/CEO | $2,971 1,150 shares | +0% | |
| 41Moderate | Aprea Therapeutics, Inc. | Bernd R. Seizinger director | $27k 10,000 shares | +29% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.